FDA approves Gilead's Bixlenvo once-daily HIV regimen for adults
- FDA approved Gilead's Bixlenvo for virologically suppressed HIV adults
- Smallest once-daily single tablet combining bictegravir and lenacapavir
- Phase 3 trials showed comparable efficacy and no new safety concerns
- Targets patients unable to take existing single-tablet regimens
*this image is generated using AI for illustrative purposes only.
The U.S. Food and Drug Administration approved Gilead Sciences (NASDAQ: GILD) Bixlenvo on Thursday for treating HIV in virologically suppressed adults. The approval introduces the smallest once-daily single tablet regimen available.
Bixlenvo combines 75 mg of bictegravir and 50 mg of lenacapavir. It serves as the first and only single-tablet option for patients managing complex regimens who cannot use other available single-tablet therapies due to antiretroviral resistance or treatment complexity.
Clinical Trial Data
The FDA decision relied on Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials. Data was presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026). Both trials evaluated Bixlenvo in adults who switched from complex multi-tablet regimens or from Biktarvy.
| Trial | Key Population Metric | Result |
|---|---|---|
| ARTISTRY-1 | Median participant age of 60 years | Comparable efficacy at Week 48 |
| ARTISTRY-2 | Switched from Biktarvy | No significant impact on weight |
In both trials, Bixlenvo demonstrated comparable efficacy in maintaining virologic suppression at Week 48. The drug was generally well tolerated with no significant or new safety concerns identified.
Patient Profile and Safety
ARTISTRY-1 enrolled the oldest study population in a Phase 3 registrational trial for HIV-1 treatment to date. Participants had a median treatment duration of 28 years. Approximately 67% had NRTI resistance, and 81% were on complex regimens due to antiretroviral resistance. At trial start, participants took between two and 11 pills daily.
The most common adverse reactions reported in at least 2% of participants across the ARTISTRY program were headache (4%), nausea (3%), and diarrhea (2%). Switching to Bixlenvo was associated with improvements in certain fasting lipid parameters and participant-reported treatment satisfaction in ARTISTRY-1.
What the Numbers Show
The clinical data highlights a significant shift toward simplifying care for experienced patients. With 81% of ARTISTRY-1 participants on complex regimens due to resistance, the successful switch to a single tablet regimen demonstrates efficacy in a high-resistance population (67% NRTI resistance). This suggests Bixlenvo addresses a specific gap for patients who cannot tolerate standard STRs.
Dosage and Administration
Bixlenvo requires a two-day initiation dose with Sunlenca (lenacapavir). Thereafter, only Bixlenvo is taken orally once a day. The combination is not approved by any regulatory authority outside the United States.
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, stated that Bixlenvo continues the company’s commitment to innovation in HIV. He noted that the pipeline includes potential daily, weekly, and longer-acting options.
Gilead Sciences shares were up 0.49% at $146.40 at the time of publication on Monday.
How might the requirement for a two-day Sunlenca initiation period impact patient adherence and real-world adoption rates for Bixlenvo?
What is the projected timeline and regulatory strategy for Gilead to seek approval for Bixlenvo in key international markets outside the United States?
Could the success of Bixlenvo in high-resistance populations accelerate the phase-out of older, complex multi-tablet regimens in standard HIV treatment guidelines?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
